医学
机器灌注
入射(几何)
随机对照试验
肝移植
移植
器官捐献
临床终点
人口统计学的
内科学
外科
捐赠
社会学
人口学
经济
物理
光学
经济增长
作者
Zoltán Czigány,Johann Pratschke,Jiří Froněk,Markus Guba,Wenzel Schöning,Dimitri Aristotle Raptis,Joachim Andrassy,Matthijs Kramer,Pavel Strnad,René Tolba,Wenjia Liu,Theresa Keller,Hannah Miller,Sandra Pavicevic,Deniz Uluk,Matěj Kočík,Isabella Lurje,Christian Trautwein,Arianeb Mehrabi,Irinel Popescu,Florian W. R. Vondran,Cynthia Ju,Frank Tacke,Ulf Peter Neumann,Georg Lurje
出处
期刊:Annals of Surgery
[Ovid Technologies (Wolters Kluwer)]
日期:2021-07-29
卷期号:274 (5): 705-712
被引量:144
标识
DOI:10.1097/sla.0000000000005110
摘要
Objective: The aim of this study was to evaluate peak serum alanine aminotransferase (ALT) and postoperative clinical outcomes after hypothermic oxygenated machine perfusion (HOPE) versus static cold storage (SCS) in extended criteria donation (ECD) liver transplantation (LT) from donation after brain death (DBD). Background: HOPE might improve outcomes in LT, particularly in high-risk settings such as ECD organs after DBD, but this hypothesis has not yet been tested in a randomized controlled clinical trial (RCT). Methods: Between September 2017 and September 2020, 46 patients undergoing ECD-DBD LT from four centers were randomly assigned to HOPE (n = 23) or SCS (n = 23). Peak-ALT levels within 7 days following LT constituted the primary endpoint. Secondary endpoints included incidence of postoperative complications [Clavien-Dindo classification (CD), Comprehensive Complication Index (CCI)], length of intensive care- (ICU) and hospital-stay, and incidence of early allograft dysfunction (EAD). Results: Demographics were equally distributed between both groups [donor age: 72 (IQR: 59–78) years, recipient age: 62 (IQR: 55–65) years, labMELD: 15 (IQR: 9–25), 38 male and 8 female recipients]. HOPE resulted in a 47% decrease in serum peak ALT [418 (IQR: 221–828) vs 796 (IQR: 477–1195) IU/L, P = 0.030], a significant reduction in 90-day complications [44% vs 74% CD grade ≥3, P = 0.036; 32 (IQR: 12–56) vs 52 (IQR: 35–98) CCI, P = 0.021], and shorter ICU- and hospital-stays [5 (IQR: 4–8) vs 8 (IQR: 5–18) days, P = 0.045; 20 (IQR: 16–27) vs 36 (IQR: 23–62) days, P = 0.002] compared to SCS. A trend toward reduced EAD was observed for HOPE (17% vs 35%; P = 0.314). Conclusion: This multicenter RCT demonstrates that HOPE, in comparison to SCS, significantly reduces early allograft injury and improves post-transplant outcomes in ECD-DBD liver transplantation.